|
|
||||||||



*
University Department of Medicine, Queen Elizabeth II Medical Center, Nedlands, Western Australia, Australia;
Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037; and
The Telethon Institute for Child Health, Subiaco, Western Australia, Australia
Tumor growth is rarely associated with a strong specific CTL response, suggesting that the immune system is ignorant of the presence of tumor because the Ags are not readily available to or are sequestered from potential effector cells. We studied the in vivo activation of naive TCR transgenic hemagglutinin (HA)-specific CD8+ T cells adoptively transferred into mice bearing HA-expressing tumor using 5,6-carboxy-succinimidyl-fluorescein-ester labeling, which allows the identification of proliferating HA-specific T cells. We demonstrate that tumor Ags are constitutively presented in the lymph nodes draining tumors and are powerfully mitogenic for responding T cells despite the absence of anti-tumor CTL responses. Importantly, this proliferative signal occurs throughout tumor growth and is still detectable 6 mo after tumor inoculation when tumor is not palpable. These results provide the first evidence that there is constitutive presentation of tumor Ags in draining lymph nodes.
This article has been cited by other articles:
![]() |
C. Jackaman, S. Cornwall, A. M. Lew, Y. Zhan, B. W. S. Robinson, and D. J. Nelson Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells Eur. Respir. J., July 1, 2009; 34(1): 162 - 175. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Broomfield, R. G. van der Most, A. C. Prosser, S. Mahendran, M. G. Tovey, M. J. Smyth, B. W. S. Robinson, and A. J. Currie Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy J. Immunol., May 1, 2009; 182(9): 5217 - 5224. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Gough, C. E. Ruby, W. L. Redmond, B. Dhungel, A. Brown, and A. D. Weinberg OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor Cancer Res., July 1, 2008; 68(13): 5206 - 5215. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Currie, R. G. van der Most, S. A. Broomfield, A. C. Prosser, M. G. Tovey, and B. W. S. Robinson Targeting the Effector Site with IFN-{alpha}{beta}-Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors J. Immunol., February 1, 2008; 180(3): 1535 - 1544. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Rudge, S. P. Barrett, B. Scott, and I. R. van Driel Infiltration of a Mesothelioma by IFN-{gamma}-Producing Cells and Tumor Rejection after Depletion of Regulatory T Cells J. Immunol., April 1, 2007; 178(7): 4089 - 4096. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Nelson and R. Ganss Tumor growth or regression: powered by inflammation J. Leukoc. Biol., October 1, 2006; 80(4): 685 - 690. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. T. Joncker, J. Helft, A. Jacquet, V. Premel, and O. Lantz Intratumor CD4 T-cell accumulation requires stronger priming than for expansion and lymphokine secretion. Cancer Res., May 15, 2006; 66(10): 5443 - 5451. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. van der Most, A. Currie, B. W.S. Robinson, and R. A. Lake Cranking the Immunologic Engine with Chemotherapy: Using Context to Drive Tumor Antigen Cross-Presentation towards Useful Antitumor Immunity Cancer Res., January 15, 2006; 66(2): 601 - 604. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Liu, P. Hu, L. A. Khawli, and A. L. Epstein Combination B7-Fc Fusion Protein Treatment and Treg Cell Depletion Therapy Clin. Cancer Res., December 1, 2005; 11(23): 8492 - 8502. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Benigni, V. S. Zimmermann, S. Hugues, S. Caserta, V. Basso, L. Rivino, E. Ingulli, L. Malherbe, N. Glaichenhaus, and A. Mondino Phenotype and Homing of CD4 Tumor-Specific T Cells Is Modulated by Tumor Bulk J. Immunol., July 15, 2005; 175(2): 739 - 748. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Lyman, C. T. Nugent, K. L. Marquardt, J. A. Biggs, E. G. Pamer, and L. A. Sherman The Fate of Low Affinity Tumor-Specific CD8+ T Cells in Tumor-Bearing Mice J. Immunol., March 1, 2005; 174(5): 2563 - 2572. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J. Sussman, R. Parihar, K. Winstead, and F. D. Finkelman Prolonged Culture of Vaccine-Primed Lymphocytes Results in Decreased Antitumor Killing and Change in Cytokine Secretion Cancer Res., December 15, 2004; 64(24): 9124 - 9130. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Boissonnas, C. Combadiere, E. Lavergne, M. Maho, C. Blanc, P. Debre, and B. Combadiere Antigen Distribution Drives Programmed Antitumor CD8 Cell Migration and Determines Its Efficiency J. Immunol., July 1, 2004; 173(1): 222 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cuenca, F. Cheng, H. Wang, J. Brayer, P. Horna, L. Gu, H. Bien, I. M. Borrello, H. I. Levitsky, and E. M. Sotomayor Extra-Lymphatic Solid Tumor Growth Is Not Immunologically Ignored and Results in Early Induction of Antigen-Specific T-Cell Anergy: Dominant Role of Cross-Tolerance to Tumor Antigens Cancer Res., December 15, 2003; 63(24): 9007 - 9015. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Jackaman, C. S. Bundell, B. F. Kinnear, A. M. Smith, P. Filion, D. van Hagen, B. W. S. Robinson, and D. J. Nelson IL-2 Intratumoral Immunotherapy Enhances CD8+ T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL-2 J. Immunol., November 15, 2003; 171(10): 5051 - 5063. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Yang, C. E. Monken, and E. C. Lattime Intratumoral Vaccination with Vaccinia-Expressed Tumor Antigen and Granulocyte Macrophage Colony-Stimulating Factor Overcomes Immunological Ignorance to Tumor Antigen Cancer Res., October 15, 2003; 63(20): 6956 - 6961. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Mullins, S. L. Sheasley, R. M. Ream, T. N.J. Bullock, Y.-X. Fu, and V. H. Engelhard Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control J. Exp. Med., October 6, 2003; 198(7): 1023 - 1034. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Nowak, B. W. S. Robinson, and R. A. Lake Synergy between Chemotherapy and Immunotherapy in the Treatment of Established Murine Solid Tumors Cancer Res., August 1, 2003; 63(15): 4490 - 4496. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Nowak, R. A. Lake, A. L. Marzo, B. Scott, W. R. Heath, E. J. Collins, J. A. Frelinger, and B. W. S. Robinson Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells J. Immunol., May 15, 2003; 170(10): 4905 - 4913. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Schuler and T. Blankenstein Cutting Edge: CD8+ Effector T Cells Reject Tumors by Direct Antigen Recognition but Indirect Action on Host Cells J. Immunol., May 1, 2003; 170(9): 4427 - 4431. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Luznik, J. E. Slansky, S. Jalla, I. Borrello, H. I. Levitsky, D. M. Pardoll, and E. J. Fuchs Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras Blood, February 15, 2003; 101(4): 1645 - 1652. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Nowak, B. W. S. Robinson, and R. A. Lake Gemcitabine Exerts a Selective Effect on the Humoral Immune Response: Implications for Combination Chemo-immunotherapy Cancer Res., April 1, 2002; 62(8): 2353 - 2358. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. T. Nguyen, A. R. Elford, K. Murakami, K. M. Garza, S. P. Schoenberger, B. Odermatt, D. E. Speiser, and P. S. Ohashi Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance J. Exp. Med., February 11, 2002; 195(4): 423 - 435. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Schell and S. S. Tevethia Control of Advanced Choroid Plexus Tumors in SV40 T Antigen Transgenic Mice Following Priming of Donor CD8+ T Lymphocytes by the Endogenous Tumor Antigen J. Immunol., December 15, 2001; 167(12): 6947 - 6956. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. W. Mullins, T. N. J. Bullock, T. A. Colella, V. V. Robila, and V. H. Engelhard Immune Responses to the HLA-A*0201-Restricted Epitopes of Tyrosinase and Glycoprotein 100 Enable Control of Melanoma Outgrowth in HLA-A*0201-Transgenic Mice J. Immunol., November 1, 2001; 167(9): 4853 - 4860. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Sotomayor, I. Borrello, F.-M. Rattis, A. G. Cuenca, J. Abrams, K. Staveley-O'Carroll, and H. I. Levitsky Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression Blood, August 15, 2001; 98(4): 1070 - 1077. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Nelson, S. Mukherjee, C. Bundell, S. Fisher, D. van Hagen, and B. Robinson Tumor Progression Despite Efficient Tumor Antigen Cross-Presentation and Effective "Arming" of Tumor Antigen-Specific CTL J. Immunol., May 1, 2001; 166(9): 5557 - 5566. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hernandez, A. Ko, and L. A. Sherman CTLA-4 Blockade Enhances the CTL Responses to the p53 Self-Tumor Antigen J. Immunol., March 15, 2001; 166(6): 3908 - 3914. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Dalyot-Herman, O. F. Bathe, and T. R. Malek Reversal of CD8+ T Cell Ignorance and Induction of Anti-Tumor Immunity by Peptide-Pulsed APC J. Immunol., December 15, 2000; 165(12): 6731 - 6737. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Marzo, B. F. Kinnear, R. A. Lake, J. J. Frelinger, E. J. Collins, B. W. S. Robinson, and B. Scott Tumor-Specific CD4+ T Cells Have a Major ""Post-Licensing"" Role in CTL Mediated Anti-Tumor Immunity J. Immunol., December 1, 2000; 165(11): 6047 - 6055. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Nelson, C. Bundell, and B. Robinson In Vivo Cross-Presentation of a Soluble Protein Antigen: Kinetics, Distribution, and Generation of Effector CTL Recognizing Dominant and Subdominant Epitopes J. Immunol., December 1, 2000; 165(11): 6123 - 6132. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Peng, J. Kjaergaard, G. E. Plautz, D. E. Weng, S. Shu, and P. A. Cohen Helper-Independent, L-Selectinlow CD8+ T Cells with Broad Anti-Tumor Efficacy Are Naturally Sensitized During Tumor Progression J. Immunol., November 15, 2000; 165(10): 5738 - 5749. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ishigami, S. Natsugoe, S. Hokita, C. Xiangming, K. Aridome, H. Iwashige, K. Tokuda, A. Nakajo, F. Miyazono, and T. Aikou Intranodal Antitumor Immunocyte Infiltration in Node-negative Gastric Cancers Clin. Cancer Res., July 1, 2000; 6(7): 2611 - 2617. [Abstract] [Full Text] |
||||
![]() |
C. Robinson, M. Callow, S. Stevenson, B. Scott, B. W. S. Robinson, and R. A. Lake Serologic Responses in Patients with Malignant Mesothelioma . Evidence for Both Public and Private Specificities Am. J. Respir. Cell Mol. Biol., May 1, 2000; 22(5): 550 - 556. [Abstract] [Full Text] |
||||
![]() |
B. Ludewig, A. F. Ochsenbein, B. Odermatt, D. Paulin, H. Hengartner, and R. M. Zinkernagel Immunotherapy with Dendritic Cells Directed against Tumor Antigens Shared with Normal Host Cells Results in Severe Autoimmune Disease J. Exp. Med., February 28, 2000; 191(5): 795 - 804. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Steinman, S. Turley, I. Mellman, and K. Inaba The Induction of Tolerance by Dendritic Cells That Have Captured Apoptotic Cells J. Exp. Med., February 7, 2000; 191(3): 411 - 416. [Full Text] [PDF] |
||||
![]() |
I. Caminschi, E. Venetsanakos, C. C. Leong, M. J. Garlepp, B. W. S. Robinson, and B. Scott Cytokine Gene Therapy of Mesothelioma . Immune and Antitumor Effects of Transfected Interleukin-12 Am. J. Respir. Cell Mol. Biol., September 1, 1999; 21(3): 347 - 356. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |